Moneycontrol PRO

Outskill Genai

you are here: HomeNewsBusinessCompaniesDishman Pharma eyes 15% topline, bottomline growth in FY12

SHOW NAMES

Trending Topics

business

Dishman Pharma eyes 15% topline, bottomline growth in FY12

In an interview with CNBC-TV18, VVS Murthy, CFO, Dishman Pharma said the company is expecting 15% top-line and bottom-line growth in FY12.

first published: Jun 13, 2011 03:30 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

The Lawyer Renting in a 120-year-old building in South Mumbai | The Tenant
Nifty On Track To End Week Above 25,500 As Bank & Metal Stocks Lead Rebound| Closing Bell Live
Can Nifty Stage A Friday Fightback After Hitting 3-Week Low? Pine Labs IPO Opens | Opening Bell Live
Nifty Stays Below 25,600 Amid Expiry-Led Volatility; Grasim, Hindalco In Focus| Closing Bell Live

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347